Table 5.
One-way SA results
| Parameters | Base case values | One-way SA Values | Incremental costs | Incremental QALY | ICUR (€/QALY gained) | ||
|---|---|---|---|---|---|---|---|
| Non prophylaxis | Palivizumab | Non- prophylaxis | Palivizumab | ||||
| Number of palivizumab injections per RSV season | – | 3.88 | – | 5 | €1,983.67 | 0.0731 | 27,152.79 |
| Risk of ICU admission | 17.80% | 17.80% | 30.00% | 11.10% | €1,370.71 | 0.0737 | 18,592.52 |
| In-hospital mortality | 2.33% | 2.33% | 0.13% | 0.09% | €1,438.90 | 0.0725 | 19,836.81 |
| Proportion of patients that experience emergency visit prior to hospital admission | 100.00% | 50.00% | €1,440.49 | 0.0731 | 19,717.70 | ||
| Hospital related costs* (+/−50%) | €3,031.30 | +50.00% (€4.546,95) | €1,354.88 | 0.0731 | 18,545.80 | ||
| −50.00% (€1515.65) | €1,523.18 | 0.0731 | 20,849.55 | ||||
| Direct recurrent wheezing management costs (+/−50%) | €749.57 | +50.00% (€1124.36) | €1,299.30 | 0.0731 | 17,785.09 | ||
| −50.00% (€.374.79) | €1,578.76 | 0.0731 | 21,610.25 | ||||
| Annual discount rate | Costs | Benefits | Costs | Benefits | |||
| 3.0% | 0.0% | €1,415.22 | 0.0799 | 17,704.00 | |||
| 5.0% | €1,453.22 | 0.0690 | 21,071.19 | ||||
| 3.0% | 1.50% | €1,439.03 | 0.0764 | 18,841.25 | |||
ICU: intensive care unit; ICUR: incremental cost-utility ratio; QALY quality adjusted life years, RSV respiratory syncytial virus, SA sensitivity analysis
*Hospital related costs included emergency visit prior hospitalization cost, hospital and ICU admission costs